Information
43 Geodudanji 1-gil, Dongnae-myeon, Chuncheon, Gangwon-do, South Korea
+82 33-243-9373
-
-
Overview
- Summary
- Boditech Med, established in 1998 as an antibody development and manufacturing company, transitioned its business focus to the point-of-care testing (POCT) market in the early 2000s, growing into a global in-vitro diagnostics (IVD) specialist. The company provides rapid and accurate diagnostic solutions for various diseases, leveraging immunoassay and molecular diagnostics technologies, with product sales in over 120 countries worldwide.Boditech Med, established in 1998 as an antibody development and manufacturing company, transitioned its business focus to the point-of-care testing (POCT) market in the early 2000s, growing into a global in-vitro diagnostics (IVD) specialist. The company provides rapid and accurate diagnostic solutions for various diseases, leveraging immunoassay and molecular diagnostics technologies, with product sales in over 120 countries worldwide.
- Key Products/Technologies
- Boditech Med offers a diverse range of point-of-care diagnostic analyzers, including the AFIAS series (AFIAS-1, AFIAS-3, AFIAS-6, AFIAS-10) and ichroma™ series (ichroma™ II, ichroma™ III, ichroma™ M2, ichroma™ M3, ichroma™-50 plus).Boditech Med offers a diverse range of point-of-care diagnostic analyzers, including the AFIAS series (AFIAS-1, AFIAS-3, AFIAS-6, AFIAS-10) and ichroma™ series (ichroma™ II, ichroma™ III, ichroma™ M2, ichroma™ M3, ichroma™-50 plus).
- The product lineup also includes blood and molecular diagnostic instruments such as hemochroma PLUS, ExAmplar, and NuActor.The product lineup also includes blood and molecular diagnostic instruments such as hemochroma PLUS, ExAmplar, and NuActor.
- Recent expansions include integrated diagnostic platforms like the AI-powered CBC blood analyzer CBChroma, compact clinical chemistry POCT device Chemichroma, mid-sized automated fecal analyzer ichroma 50 Plus, urine analyzer Urochroma, and next-generation hemoglobin analyzer Hemochroma 2 Plus.Recent expansions include integrated diagnostic platforms like the AI-powered CBC blood analyzer CBChroma, compact clinical chemistry POCT device Chemichroma, mid-sized automated fecal analyzer ichroma 50 Plus, urine analyzer Urochroma, and next-generation hemoglobin analyzer Hemochroma 2 Plus.
- The company develops and supplies diagnostic kits covering over 80 different markers for conditions such as cardiac, cancer, diabetes, hormones, infections, autoimmune diseases, organ function, and therapeutic drug monitoring (TDM).The company develops and supplies diagnostic kits covering over 80 different markers for conditions such as cardiac, cancer, diabetes, hormones, infections, autoimmune diseases, organ function, and therapeutic drug monitoring (TDM).
- Proprietary fluorescence immunoassay technology and time-resolved fluorescence (TRF) technology, offering 10 to 100 times higher sensitivity, are key technological strengths.Proprietary fluorescence immunoassay technology and time-resolved fluorescence (TRF) technology, offering 10 to 100 times higher sensitivity, are key technological strengths.
- Core Advantages
- The company's leading position in the point-of-care testing (POCT) sector, backed by over 20 years of industry experience.The company's leading position in the point-of-care testing (POCT) sector, backed by over 20 years of industry experience.
- A comprehensive diagnostic portfolio of over 100 products for various diseases, including infectious diseases, diabetes, cardiovascular conditions, cancer, and hormones, demonstrating strong market responsiveness.A comprehensive diagnostic portfolio of over 100 products for various diseases, including infectious diseases, diabetes, cardiovascular conditions, cancer, and hormones, demonstrating strong market responsiveness.
- The AFIAS platform's speed and ease of use, providing results within 12 minutes from a small blood sample.The AFIAS platform's speed and ease of use, providing results within 12 minutes from a small blood sample.
- Robust innovative technology development capabilities, with over 15% of revenue invested in R&D and more than 85 patents.Robust innovative technology development capabilities, with over 15% of revenue invested in R&D and more than 85 patents.
- A powerful global distribution network exporting diagnostic products to over 120-140 countries worldwide.A powerful global distribution network exporting diagnostic products to over 120-140 countries worldwide.
- A differentiated medical diagnostic system integrating bio and IT technologies, including AI-based cell analysis and automated liquid handling functions.A differentiated medical diagnostic system integrating bio and IT technologies, including AI-based cell analysis and automated liquid handling functions.
- Target Industrie
- Boditech Med's diagnostic solutions find application across diverse healthcare settings, including hospitals, emergency rooms, and home care.Boditech Med's diagnostic solutions find application across diverse healthcare settings, including hospitals, emergency rooms, and home care.
- The solutions particularly support rapid diagnosis and treatment decisions in primary care clinics and local medical facilities.The solutions particularly support rapid diagnosis and treatment decisions in primary care clinics and local medical facilities.
- Beyond human diagnostics, the company extends its business scope through the development and supply of diagnostic products for veterinary applications.Beyond human diagnostics, the company extends its business scope through the development and supply of diagnostic products for veterinary applications.
- Major Markets
- Middle East and North Africa, Africa (general)Middle East and North Africa, Africa (general)
- China, India, Philippines, VietnamChina, India, Philippines, Vietnam
- UK, Switzerland, Norway, Iceland, Montenegro, Albania, Macedonia, ItalyUK, Switzerland, Norway, Iceland, Montenegro, Albania, Macedonia, Italy
- USAUSA
- EcuadorEcuador
- Certifications/Patents
- Designation as an 'Innovative Medical Device Company' by the Ministry of Health and Welfare, acknowledging technological excellence and business competitiveness.Designation as an 'Innovative Medical Device Company' by the Ministry of Health and Welfare, acknowledging technological excellence and business competitiveness.
- Certification for 14 diagnostic devices and 142 diagnostic kits under the European In Vitro Diagnostic Regulation (CE-IVDR, 2017/746).Certification for 14 diagnostic devices and 142 diagnostic kits under the European In Vitro Diagnostic Regulation (CE-IVDR, 2017/746).
- Completion of Saudi Food and Drug Authority (SFDA) certification for 26 AFIAS diagnostic kits.Completion of Saudi Food and Drug Authority (SFDA) certification for 26 AFIAS diagnostic kits.
- The i-CHROMA™ system holds Korean Food & Drug Administration (KFDA) approval, CE Marking, and ISO 13485 certification.The i-CHROMA™ system holds Korean Food & Drug Administration (KFDA) approval, CE Marking, and ISO 13485 certification.
- Acquisition of Ministry of Food and Drug Safety (MFDS) export licenses for 14 therapeutic drug monitoring (TDM) products.Acquisition of Ministry of Food and Drug Safety (MFDS) export licenses for 14 therapeutic drug monitoring (TDM) products.
- Development and ownership of over 85 patents through a research team of more than 100 individuals.Development and ownership of over 85 patents through a research team of more than 100 individuals.
Introduction
Location
43 Geodudanji 1-gil, Dongnae-myeon, Chuncheon, Gangwon-do, South Korea
클릭하여 위치 살펴보기
